{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T09:59:01Z","timestamp":1780048741848,"version":"3.53.1"},"reference-count":119,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1038\/nrd2087","type":"journal-article","created":{"date-parts":[[2006,10,2]],"date-time":"2006-10-02T15:11:10Z","timestamp":1159801870000},"page":"845-854","source":"Crossref","is-referenced-by-count":243,"title":["Novel pharmacological targets for the treatment of Parkinson's disease"],"prefix":"10.1038","volume":"5","author":[{"given":"Anthony H. V.","family":"Schapira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwan","family":"Bezard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Brotchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Calon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham L.","family":"Collingridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borris","family":"Ferger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian","family":"Hengerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Jenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas Le","family":"Nov\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A.","family":"Obeso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Schwarzschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Spampinato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giora","family":"Davidai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFnrd2087_CR1","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak, H. et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197\u2013211 (2003).","journal-title":"Neurobiol. Aging"},{"key":"BFnrd2087_CR2","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1056\/NEJM200005183422004","volume":"34","author":"O Rascol","year":"2000","unstructured":"Rascol, O. et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N. Engl. J. Med. 34, 1484\u20131491 2000).","journal-title":"N. Engl. J. Med."},{"key":"BFnrd2087_CR3","first-page":"1044","volume":"61","author":"RG Holloway","year":"2004","unstructured":"Holloway, R. G. et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch. Neurol. 61, 1044\u20131053 (2004).","journal-title":"Arch. Neurol."},{"key":"BFnrd2087_CR4","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/mds.20276","volume":"20","author":"R Katzenschlager","year":"2005","unstructured":"Katzenschlager, R. et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov. Disord. 20, 151\u2013157 (2005).","journal-title":"Mov. Disord."},{"key":"BFnrd2087_CR5","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1212\/WNL.65.2_suppl_1.S11","volume":"65","author":"W Poewe","year":"2005","unstructured":"Poewe, W. & Luessi, F. Clinical studies with transdermal rotigotine in early Parkinson's disease. Neurology 65, S11\u2013S14 (2005).","journal-title":"Neurology"},{"key":"BFnrd2087_CR6","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1124\/jpet.102.039875","volume":"303","author":"A Newman-Tancredi","year":"2002","unstructured":"Newman-Tancredi, A. et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and \u03b1(1)\/\u03b1(2)-adrenoceptor. J. Pharmacol. Exp. Ther. 303, 805\u2013814 (2002).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFnrd2087_CR7","first-page":"33","volume-title":"Principles of Treatment in Parkinson's Disease","author":"P Jenner","year":"2005","unstructured":"Jenner, P. in Principles of Treatment in Parkinson's Disease (eds Schapira, A. H. V. & Olanow, C. W.) 33\u2013359 (Elsevier, Philadelphia, 2005)."},{"issue":"Suppl. 4","key":"BFnrd2087_CR8","first-page":"iv37","volume":"252","author":"S Fahn","year":"2005","unstructured":"Fahn, S. Does levodopa slow or hasten the rate of progression of Parkinson's disease? J. Neurol. 252 (Suppl. 4), iv37\u2013iv42 (2005).","journal-title":"J. Neurol."},{"key":"BFnrd2087_CR9","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/S1471-1931(00)00030-6","volume":"23","author":"W Olanow","year":"2000","unstructured":"Olanow, W., Schapira, A. H. & Rascol, O. Continuous dopamine-receptor stimulation in early Parkinson's disease. Trends Neurosci. 23, S117\u2013S126 (2000).","journal-title":"Trends Neurosci."},{"key":"BFnrd2087_CR10","doi-asserted-by":"publisher","first-page":"S92","DOI":"10.1016\/S1471-1931(00)00026-4","volume":"23","author":"F Calon","year":"2000","unstructured":"Calon, F. et al. Dopamine-receptor stimulation: biobehavioral and biochemical consequences. Trends Neurosci. 23, S92\u2013S100 (2000).","journal-title":"Trends Neurosci."},{"key":"BFnrd2087_CR11","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1136\/jnnp.74.8.1071","volume":"74","author":"DJ Brooks","year":"2003","unstructured":"Brooks, D. J. & Sagar, H. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. J. Neurol. Neurosurg. Psychiatry 74, 1071\u20131079 (2003).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrd2087_CR12","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.tips.2005.05.002","volume":"26","author":"NB Mercuri","year":"2005","unstructured":"Mercuri, N. B. & Bernardi, G. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy? Trends Pharmacol. Sci. 26, 341\u2013344 (2005).","journal-title":"Trends Pharmacol. Sci."},{"key":"BFnrd2087_CR13","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/BF02257646","volume":"2","author":"EK Perry","year":"1990","unstructured":"Perry, E. K. et al. Cholinergic nicotinic and muscarinic receptors in dementia of Alzheimer, Parkinson and Lewy body types. J. Neural. Transm. Park. Dis. Dement. Sect. 2, 149\u2013158 (1990).","journal-title":"J. Neural. Transm. Park. Dis. Dement. Sect."},{"key":"BFnrd2087_CR14","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/j.1600-0404.1995.tb00443.x","volume":"91","author":"M Asahina","year":"1995","unstructured":"Asahina, M. et al. Hypersensitivity of cortical muscarinic receptors in Parkinson's disease demonstrated by PET. Acta Neurol. Scand. 91, 437\u2013443 (1995).","journal-title":"Acta Neurol. Scand."},{"key":"BFnrd2087_CR15","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.tins.2004.06.008","volume":"27","author":"M Quik","year":"2004","unstructured":"Quik, M. Smoking, nicotine and Parkinson's disease. Trends Neurosci. 27, 561\u2013568 (2004).","journal-title":"Trends Neurosci."},{"key":"BFnrd2087_CR16","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/0006-8993(94)91032-4","volume":"636","author":"R Rodriguez-Puertas","year":"1994","unstructured":"Rodriguez-Puertas, R., Pazos, A. & Pascual, J. Cholinergic markers in degenerative parkinsonism: autoradiographic demonstration of high-affinity choline uptake carrier hyperactivity. Brain Res. 636, 327\u2013332 (1994).","journal-title":"Brain Res."},{"key":"BFnrd2087_CR17","doi-asserted-by":"crossref","unstructured":"Katzenschlager, R. et al. Anticholinergics for symptomatic management of Parkinson's disease. Cochrane Database Syst Rev. CD003735 (2003).","DOI":"10.1002\/14651858.CD003735"},{"key":"BFnrd2087_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/gps.993","volume":"19","author":"I Leroi","year":"2004","unstructured":"Leroi, I. et al. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int. J. Geriatr. Psychiatry 19, 1\u20138 (2004).","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"BFnrd2087_CR19","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1136\/jnnp.72.6.708","volume":"72","author":"D Aarsland","year":"2002","unstructured":"Aarsland, D. et al. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J. Neurol. Neurosurg. Psychiatry 72, 708\u2013712 (2002).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrd2087_CR20","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa041470","volume":"351","author":"M Emre","year":"2004","unstructured":"Emre, M. et al. Rivastigmine for dementia associated with Parkinson's disease. N. Engl. J. Med. 351, 2509\u20132518 (2004).","journal-title":"N. Engl. J. Med."},{"key":"BFnrd2087_CR21","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s007020100008","volume":"108","author":"EA Werber","year":"2001","unstructured":"Werber, E. A. & Rabey, J. M. The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia. J. Neural Transm. 108, 1319\u20131325 (2001).","journal-title":"J. Neural Transm."},{"key":"BFnrd2087_CR22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s100720200022","volume":"23","author":"G Fabbrini","year":"2002","unstructured":"Fabbrini, G. et al. Donepezil in the treatment of hallucinations and delusions in Parkinson's disease. Neurol. Sci. 23, 41\u201343 (2002).","journal-title":"Neurol. Sci."},{"key":"BFnrd2087_CR23","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1111\/j.1460-9568.1996.tb01206.x","volume":"8","author":"N Le Novere","year":"1996","unstructured":"Le Novere, N., Zoli, M. & Changeux, J. P. Neuronal nicotinic receptor \u03b16 subunit mRNA is selectively concentrated in catecholaminergic nuclei of the rat brain. Eur. J. Neurosci. 8, 2428\u20132439 (1996).","journal-title":"Eur. J. Neurosci."},{"key":"BFnrd2087_CR24","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/S0006-8993(00)03087-0","volume":"888","author":"G Costa","year":"2001","unstructured":"Costa, G., Abin-Carriquiry, J. A. & Dajas, F. Nicotine prevents striatal dopamine loss produced by 6-hydroxydopamine lesion in the substantia nigra. Brain Res. 888, 336\u2013342 (2001).","journal-title":"Brain Res."},{"key":"BFnrd2087_CR25","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S0306-4522(01)00488-2","volume":"109","author":"G Jeyarasasingam","year":"2002","unstructured":"Jeyarasasingam, G., Tompkins, L. & Quik, M. Stimulation of non-\u03b17 nicotinic receptors partially protects dopaminergic neurons from 1-methyl-4-phenylpyridinium-induced toxicity in culture. Neuroscience 109, 275\u2013285 (2002).","journal-title":"Neuroscience"},{"key":"BFnrd2087_CR26","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1002\/mds.20029","volume":"19","author":"MF Allam","year":"2004","unstructured":"Allam, M. F. et al. Smoking and Parkinson's disease: systematic review of prospective studies. Mov. Disord. 19, 614\u2013621 (2004).","journal-title":"Mov. Disord."},{"key":"BFnrd2087_CR27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s002130050265","volume":"131","author":"G Lucas","year":"1997","unstructured":"Lucas, G., Bonhomme, N., De Deurwaerd\u00e8re, P., Le Moal, M. & Spampinato, U. 8-OH-DPAT, a 5-HT1A agonist and ritanserin, a 5-HT2A\/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release. Psychopharmacology 131, 57\u201363 (1997).","journal-title":"Psychopharmacology"},{"key":"BFnrd2087_CR28","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1046\/j.1471-4159.1999.0731033.x","volume":"73","author":"P De Deurwaerd\u00e8re","year":"1999","unstructured":"De Deurwaerd\u00e8re, P. & Spampinato, U. Role of serotonin(2A) and serotonin(2B\/2C) receptor subtypes in the control of accumbal and striatal dopamine release elicited in vivo by dorsal raphe nucleus electrical stimulation. J. Neurochem. 73, 1033\u201342 (1999).","journal-title":"J. Neurochem."},{"key":"BFnrd2087_CR29","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.1523\/JNEUROSCI.0112-04.2004","volume":"24","author":"P De Deurwaerd\u00e8re","year":"2004","unstructured":"De Deurwaerd\u00e8re, P., Navailles, S., Berg, K. A., Clarke, W. P. & Spampinato, U. Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens. J. Neurosci. 24, 3235\u20133241 (2004).","journal-title":"J. Neurosci."},{"issue":"Suppl. 3","key":"BFnrd2087_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1046\/j.1468-1331.9.s3.1.x","volume":"9","author":"SL Nicholson","year":"2002","unstructured":"Nicholson, S. L. & Brotchie, J. M. 5-hydroxytryptamine (5-HT, serotonin) and Parkinson's disease- opportunities for novel therapeutics to reduce the problems of levodopa therapy. Eur. J. Neurol. 9 (Suppl. 3), 1\u20136 (2002).","journal-title":"Eur. J. Neurol."},{"key":"BFnrd2087_CR31","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/1098-2396(20010315)39:4<288::AID-SYN1011>3.0.CO;2-V","volume":"39","author":"D Frechilla","year":"2001","unstructured":"Frechilla, D. et al. Serotonin 5-HT(1A) receptor expression is selectively enhanced in the striosomal compartment of chronic parkinsonian monkeys. Synapse 39, 288\u2013296 (2001).","journal-title":"Synapse"},{"key":"BFnrd2087_CR32","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/0169-328X(95)00004-C","volume":"29","author":"S Numan","year":"1995","unstructured":"Numan, S. et al. Increased expression of 5HT2 receptor mRNA in rat striatum following 6-OHDA lesions of the adult nigrostriatal pathway. Brain Res. Mol. Brain Res. 29, 391\u2013396 (1995).","journal-title":"Brain Res. Mol. Brain Res."},{"key":"BFnrd2087_CR33","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1002\/1531-8257(200011)15:6<1064::AID-MDS1002>3.0.CO;2-C","volume":"15","author":"SH Fox","year":"2000","unstructured":"Fox, S. H. & Brotchie, J. M. 5-HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease. Mov. Disord. 15, 1064\u20131069 (2000).","journal-title":"Mov. Disord."},{"key":"BFnrd2087_CR34","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1212\/WNL.57.10.1829","volume":"57","author":"F Bibbiani","year":"2001","unstructured":"Bibbiani, F., Oh, J. D. & Chase, T. N. Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology. 57, 1829\u20131834 (2001).","journal-title":"Neurology."},{"key":"BFnrd2087_CR35","first-page":"412","volume":"19","author":"C Chassain","year":"2004","unstructured":"Chassain, C. & Durif, F. M. Modulation of serotonin receptors in MPTP-lesioned monkeys. Mov. Disord. 19, 412 (2004).","journal-title":"Mov. Disord."},{"key":"BFnrd2087_CR36","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/00002826-200403000-00003","volume":"27","author":"CW Olanow","year":"2004","unstructured":"Olanow, C. W. et al. Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin. Neuropharmacol. 27, 58\u201362 (2004).","journal-title":"Clin. Neuropharmacol."},{"key":"BFnrd2087_CR37","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/mds.20370","volume":"20","author":"W Bara-Jimenez","year":"2005","unstructured":"Bara-Jimenez, W. et al. Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease. Mov. Disord. 20, 932\u2013936 (2005).","journal-title":"Mov. Disord."},{"key":"BFnrd2087_CR38","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/00002826-199402000-00008","volume":"17","author":"V Bonifati","year":"1994","unstructured":"Bonifati, V. et al. Buspirone in levodopa-induced dyskinesias. Clin. Neuropharmacol. 17, 73\u201382 (1994).","journal-title":"Clin. Neuropharmacol."},{"key":"BFnrd2087_CR39","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1006\/exnr.2002.8009","volume":"177","author":"JD Oh","year":"2002","unstructured":"Oh, J. D., Bibbiani, F. & Chase, T. N. Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models. Exp. Neurol. 177, 557\u2013564 (2002).","journal-title":"Exp. Neurol."},{"key":"BFnrd2087_CR40","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1006\/exnr.1998.6792","volume":"151","author":"SH Fox","year":"1998","unstructured":"Fox, S. H., Moser, B. & Brotchie, J. M. Behavioral effects of 5-HT2C receptor antagonism in the substantia nigra zona reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Exp. Neurol. 151, 35\u201349 (1998).","journal-title":"Exp. Neurol."},{"key":"BFnrd2087_CR41","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0014-2999(00)00238-7","volume":"398","author":"SH Fox","year":"2000","unstructured":"Fox, S. H. & Brotchie, J. M. 5-HT(2C) receptor antagonists enhance the behavioural response to dopamine D(1) receptor agonists in the 6-hydroxydopamine-lesioned rat. Eur. J. Pharmacol. 398, 59\u201364 (2000).","journal-title":"Eur. J. Pharmacol."},{"key":"BFnrd2087_CR42","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1097\/00002826-199310000-00004","volume":"16","author":"B Gomez-Mancilla","year":"1993","unstructured":"Gomez-Mancilla, B. & Bedard, P. J. Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys. Clin. Neuropharmacol. 16, 418\u2013427 (1993).","journal-title":"Clin. Neuropharmacol."},{"key":"BFnrd2087_CR43","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/(SICI)1098-2396(199612)24:4<349::AID-SYN5>3.0.CO;2-D","volume":"24","author":"CR Ashby Jr","year":"1996","unstructured":"Ashby, C. R. Jr. & Wang, R. Y. Pharmacological actions of the atypical antipsychotic drug clozapine: a review. Synapse 24, 349\u2013394 (1996).","journal-title":"Synapse"},{"key":"BFnrd2087_CR44","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/0893-133X(94)00129-N","volume":"14","author":"FP Bymaster","year":"1996","unstructured":"Bymaster, F. P. et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14, 87\u201396 (1996).","journal-title":"Neuropsychopharmacology"},{"key":"BFnrd2087_CR45","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1212\/WNL.52.4.771","volume":"52","author":"R Grondin","year":"1999","unstructured":"Grondin, R. et al. D1 receptor blockade improves L-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys. Neurology 52, 771\u2013776 (1999).","journal-title":"Neurology"},{"key":"BFnrd2087_CR46","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1212\/01.WNL.0000110317.52453.6C","volume":"62","author":"F Durif","year":"2004","unstructured":"Durif, F. et al. Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology 62, 381\u2013388 (2004).","journal-title":"Neurology"},{"key":"BFnrd2087_CR47","first-page":"295","volume":"75","author":"R Katzenschlager","year":"2004","unstructured":"Katzenschlager, R. et al. Low dose quetiapine for drug induced dyskinesias in Parkinson's disease: a double blind cross over study. J. Neurol. Neurosurg. Psychiatry 75, 295\u2013297 (2004).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrd2087_CR48","doi-asserted-by":"publisher","first-page":"9107","DOI":"10.1523\/JNEUROSCI.23-27-09107.2003","volume":"23","author":"MM Iravani","year":"2003","unstructured":"Iravani, M. M. et al. 3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates. J. Neurosci. 23, 9107\u20139115 (2003).","journal-title":"J. Neurosci."},{"key":"BFnrd2087_CR49","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1212\/01.WNL.0000161841.41885.80","volume":"64","author":"KA Chung","year":"2005","unstructured":"Chung, K. A., Carlson, N. E. & Nutt, J. G. Short-term paroxetine treatment does not alter the motor response to levodopa in PD. Neurology 64, 1797\u20131798 (2005).","journal-title":"Neurology"},{"key":"BFnrd2087_CR50","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/00002826-200307000-00005","volume":"26","author":"G Meco","year":"2003","unstructured":"Meco, G. et al. Mirtazapine in L-dopa-induced dyskinesias. Clin. Neuropharmacol. 26, 179\u2013181 (2003).","journal-title":"Clin. Neuropharmacol."},{"key":"BFnrd2087_CR51","doi-asserted-by":"crossref","unstructured":"Parsons, C. G., Danysz, W. & Quack, G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist-a review of preclinical data. Neuropharmacology 38, 735\u2013767 (999).","DOI":"10.1016\/S0028-3908(99)00019-2"},{"key":"BFnrd2087_CR52","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.expneurol.2004.05.004","volume":"188","author":"JE Nash","year":"2004","unstructured":"Nash, J. E. et al. The NR2B-selective NMDA receptor antagonist CP-101, 606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease. Exp. Neurol. 188, 471\u2013479 (2004).","journal-title":"Exp. Neurol."},{"key":"BFnrd2087_CR53","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.nbd.2003.10.007","volume":"15","author":"A Hadj Tahar","year":"2004","unstructured":"Hadj Tahar, A. et al. Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys. Neurobiol. Dis. 15, 171\u2013176 (2004).","journal-title":"Neurobiol. Dis."},{"key":"BFnrd2087_CR54","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/(SICI)1096-9861(19980105)390:1<91::AID-CNE8>3.0.CO;2-L","volume":"390","author":"TJ Counihan","year":"1998","unstructured":"Counihan, T. J. et al. Expression of N-methyl-D-aspartate receptor subunit mRNA in the human brain: mesencephalic dopaminergic neurons. J. Comp. Neurol. 390, 91\u2013101 (1998).","journal-title":"J. Comp. Neurol."},{"key":"BFnrd2087_CR55","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/sj.bjp.0705644","volume":"141","author":"B Feng","year":"2004","unstructured":"Feng, B. et al. Structure-activity analysis of a novel NR2C\/NR2D-preferring NMDA receptor antagonist: 1-(phenanthrene-2-carbonyl) piperazine-2,3-dicarboxylic acid. Br. J. Pharmacol. 141, 508\u2013516 (2004).","journal-title":"Br. J. Pharmacol."},{"key":"BFnrd2087_CR56","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/nn1040","volume":"6","author":"B Picconi","year":"2003","unstructured":"Picconi, B. et al. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nature Neurosci. 6, 501\u2013506 (2003).","journal-title":"Nature Neurosci."},{"key":"BFnrd2087_CR57","doi-asserted-by":"publisher","first-page":"13668","DOI":"10.1073\/pnas.1835724100","volume":"100","author":"MJ Marino","year":"2003","unstructured":"Marino, M. J. et al. Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment. Proc. Natl Acad. Sci. USA 100, 13668\u201313673 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd2087_CR58","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ejphar.2003.12.023","volume":"486","author":"MJ O'Neill","year":"2004","unstructured":"O'Neill, M. J. et al. Neurotrophic actions of the novel AMPA receptor potentiator, LY404187, in rodent models of Parkinson's disease. Eur. J. Pharmacol. 486, 163\u2013174 (2004).","journal-title":"Eur. J. Pharmacol."},{"key":"BFnrd2087_CR59","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.neuropharm.2004.03.005","volume":"47","author":"JC More","year":"2004","unstructured":"More, J. C. et al. Characterisation of UBP296: a novel, potent and selective kainate receptor antagonist. Neuropharmacology 47, 46\u201364 (2004).","journal-title":"Neuropharmacology"},{"key":"BFnrd2087_CR60","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/0006-8993(95)00229-J","volume":"680","author":"F Calon","year":"1995","unstructured":"Calon, F. et al. Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA receptors in the striatopallidal complex. Brain Res. 680, 43\u201352 (1995).","journal-title":"Brain Res."},{"key":"BFnrd2087_CR61","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/mds.10343","volume":"18","author":"F Calon","year":"2003","unstructured":"Calon, F. et al. Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications. Mov. Disord. 18, 241\u2013253 (2003).","journal-title":"Mov. Disord."},{"key":"BFnrd2087_CR62","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.pharmthera.2004.10.007","volume":"105","author":"K Xu","year":"2005","unstructured":"Xu, K., Bastia, E. & Schwarzschild, M. Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease. Pharmacol. Ther. 105, 267\u2013310 (2005).","journal-title":"Pharmacol. Ther."},{"key":"BFnrd2087_CR63","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1517\/13543784.14.6.729","volume":"14","author":"P Jenner","year":"2005","unstructured":"Jenner, P. Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease. Expert Opin. Investig. Drugs. 14, 729\u2013738 (2005).","journal-title":"Expert Opin. Investig. Drugs."},{"key":"BFnrd2087_CR64","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/0169-328X(92)90173-9","volume":"14","author":"JS Fink","year":"1992","unstructured":"Fink, J S. et al. Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum. Brain Res. Mol. Brain Res. 14, 186\u2013195 (1992).","journal-title":"Brain Res. Mol. Brain Res."},{"key":"BFnrd2087_CR65","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1212\/WNL.52.8.1673","volume":"52","author":"R Grondin","year":"1999","unstructured":"Grondin, R. et al. Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys. Neurology 52, 1673\u20131637 (1999).","journal-title":"Neurology"},{"key":"BFnrd2087_CR66","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1212\/01.WNL.0000095211.71092.A0","volume":"61","author":"A Mori","year":"2003","unstructured":"Mori, A. & Shindou, T. Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: a potential mechanism for the antiparkinsonian effects of A2A antagonists. Neurology 61, S44\u2013S48 (2003).","journal-title":"Neurology"},{"key":"BFnrd2087_CR67","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1212\/01.WNL.0000073136.00548.D4","volume":"61","author":"W Bara-Jimenez","year":"2003","unstructured":"Bara-Jimenez, W. et al. Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology 61, 293\u2013296 (2003).","journal-title":"Neurology"},{"key":"BFnrd2087_CR68","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1212\/01.WNL.0000081227.84197.0B","volume":"61","author":"RA Hauser","year":"2003","unstructured":"Hauser, R. A., Hubble, J. P. & Truong, D. D. Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology 61, 297\u2013303 (2003).","journal-title":"Neurology"},{"key":"BFnrd2087_CR69","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1212\/01.WNL.0000095213.86899.21","volume":"61","author":"A Ascherio","year":"2003","unstructured":"Ascherio, A. & Chen, H. Caffeinated clues from epidemiology of Parkinson's disease. Neurology 61, S51\u2013S54 (2003).","journal-title":"Neurology"},{"key":"BFnrd2087_CR70","doi-asserted-by":"publisher","first-page":"RC143","DOI":"10.1523\/JNEUROSCI.21-10-j0001.2001","volume":"21","author":"JF Chen","year":"2001","unstructured":"Chen, J. F. et al. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J. Neurosci. 21, RC143 (2001).","journal-title":"J. Neurosci."},{"key":"BFnrd2087_CR71","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1523\/JNEUROSCI.22-03-01054.2002","volume":"22","author":"S Fredduzzi","year":"2002","unstructured":"Fredduzzi, S. et al. Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors. J. Neurosci. 22, 1054\u20131062 (2002).","journal-title":"J. Neurosci."},{"key":"BFnrd2087_CR72","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S0014-4886(03)00250-4","volume":"184","author":"F Bibbiani","year":"2003","unstructured":"Bibbiani, F. et al. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Exp. Neurol. 184, 285\u2013294 (2003).","journal-title":"Exp. Neurol."},{"key":"BFnrd2087_CR73","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1212\/01.WNL.0000095206.44418.5C","volume":"61","author":"K Fuxe","year":"2003","unstructured":"Fuxe, K. et al. Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson's disease. Neurology 61, S19\u2013S23 (2003).","journal-title":"Neurology"},{"key":"BFnrd2087_CR74","doi-asserted-by":"publisher","first-page":"10414","DOI":"10.1523\/JNEUROSCI.3660-05.2005","volume":"25","author":"A Kachroo","year":"2005","unstructured":"Kachroo, A. et al. Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice. J. Neurosci. 25, 10414\u201310419 (2005).","journal-title":"J. Neurosci."},{"key":"BFnrd2087_CR75","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1038\/sj.npp.1300444","volume":"29","author":"R Coccurello","year":"2004","unstructured":"Coccurello, R., Breysse, N. & Amalric, M. Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats. Neuropsychopharmacology 29, 1451\u2013161 (2004).","journal-title":"Neuropsychopharmacology"},{"key":"BFnrd2087_CR76","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/35086062","volume":"2","author":"E Bezard","year":"2001","unstructured":"Bezard, E., Brotchie, J. M. & Gross, C. E. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nature Rev. Neurosci. 2, 577\u2013588 (2001).","journal-title":"Nature Rev. Neurosci."},{"key":"BFnrd2087_CR77","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1093\/jnen\/61.2.186","volume":"61","author":"F Calon","year":"2002","unstructured":"Calon, F. et al. Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias. J. Neuropathol. Exp. Neurol. 61, 186\u2013196 (2002).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"BFnrd2087_CR78","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1006\/exnr.2001.7727","volume":"171","author":"B Henry","year":"2001","unstructured":"Henry, B. et al. \u03bc- and \u03b4-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Exp. Neurol. 171, 139\u2013146 (2001).","journal-title":"Exp. Neurol."},{"key":"BFnrd2087_CR79","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/S0028-3908(03)00249-1","volume":"45","author":"P Samadi","year":"2003","unstructured":"Samadi, P., Gregoire, L. & Bedard, P. J. Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems. Neuropharmacology 45, 954\u2013963 (2003).","journal-title":"Neuropharmacology"},{"key":"BFnrd2087_CR80","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1002\/mds.10693","volume":"19","author":"S Fox","year":"2004","unstructured":"Fox, S. et al. Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease. Mov. Disord. 19, 554\u2013560 (2004).","journal-title":"Mov. Disord."},{"key":"BFnrd2087_CR81","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/mds.870090410","volume":"9","author":"O Rascol","year":"1994","unstructured":"Rascol, O. et al. Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease. Mov. Disord. 9, 437\u2013440 (1994).","journal-title":"Mov. Disord."},{"key":"BFnrd2087_CR82","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1146\/annurev.pa.26.040186.000423","volume":"26","author":"V Hollt","year":"1986","unstructured":"Hollt, V. Opioid peptide processing and receptor selectivity. Annu. Rev. Pharmacol. Toxicol. 26, 59\u201377 (1986).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"BFnrd2087_CR83","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/j.lfs.2004.10.024","volume":"76","author":"W Sadee","year":"2005","unstructured":"Sadee, W., Wang, D. & Bilsky, E. J. Basal opioid receptor activity, neutral antagonists, and therapeutic opportunities. Life Sci. 76, 1427\u20131437 (2005).","journal-title":"Life Sci."},{"key":"BFnrd2087_CR84","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1210\/edrv-9-2-200","volume":"9","author":"WF Simonds","year":"1988","unstructured":"Simonds, W. F. The molecular basis of opioid receptor function. Endocr Rev. 9, 200\u2013212 (1988).","journal-title":"Endocr Rev."},{"key":"BFnrd2087_CR85","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/0166-2236(95)93946-U","volume":"18","author":"A Mansour","year":"1995","unstructured":"Mansour, A. et al. Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci. 18, 22\u201329 (1995).","journal-title":"Trends Neurosci."},{"key":"BFnrd2087_CR86","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1212\/WNL.66.10_suppl_4.S10","volume":"66","author":"AH Schapira","year":"2006","unstructured":"Schapira, A. H. Etiology of Parkinson's disease. Neurology 66, S10\u2013S23 (2006).","journal-title":"Neurology"},{"key":"BFnrd2087_CR87","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1126\/science.1087753","volume":"302","author":"TM Dawson","year":"2003","unstructured":"Dawson, T. M. & Dawson, V. L. Molecular pathways of neurodegeneration in Parkinson's disease. Science. 302, 819\u2013822 (2003).","journal-title":"Science."},{"key":"BFnrd2087_CR88","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1001\/archneur.59.10.1541","volume":"59","author":"CW Shults","year":"2002","unstructured":"Shults, C. W. et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch. Neurol. 59, 1541\u20131550 (2002).","journal-title":"Arch. Neurol."},{"key":"BFnrd2087_CR89","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1126\/science.1060885","volume":"292","author":"S Hunot","year":"2001","unstructured":"Hunot, S. & Flavell, R. A. Apoptosis. Death of a monopoly? Science 292, 865\u2013866 (2001).","journal-title":"Science"},{"key":"BFnrd2087_CR90","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1001\/archneur.60.8.1059","volume":"60","author":"H Chen","year":"2003","unstructured":"Chen, H. et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch. Neurol. 60, 1059\u20131064 (2003).","journal-title":"Arch. Neurol."},{"key":"BFnrd2087_CR91","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S1474-4422(04)00769-0","volume":"3","author":"AH Schapira","year":"2004","unstructured":"Schapira, A. H. Disease modification in Parkinson's disease. Lancet Neurol. 3, 362\u2013368 (2004).","journal-title":"Lancet Neurol."},{"key":"BFnrd2087_CR92","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1111\/j.1471-4159.2005.03625.x","volume":"96","author":"MM Iravani","year":"2006","unstructured":"Iravani, M. M., Haddon, C. O., Cooper, J. M., Jenner, P. & Schapira, A. H. Pramipexole protects against MPTP toxicity in non-human primates. J. Neurochem. 96, 1315\u20131321 (2006).","journal-title":"J. Neurochem."},{"key":"BFnrd2087_CR93","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1111\/j.1471-4159.2004.02804.x","volume":"91","author":"M Gu","year":"2004","unstructured":"Gu, M. et al. Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. J. Neurochem. 91, 1075\u20131081 (2004).","journal-title":"J. Neurochem."},{"key":"BFnrd2087_CR94","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/ana.10609","volume":"54","author":"AL Whone","year":"2003","unstructured":"Whone, A. L. et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann. Neurol. 54, 93\u2013101 (2003).","journal-title":"Ann. Neurol."},{"key":"BFnrd2087_CR95","doi-asserted-by":"crossref","unstructured":"Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287, 1653\u20131661 (2002).","DOI":"10.1001\/jama.287.13.1653"},{"key":"BFnrd2087_CR96","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1001\/jama.291.3.358","volume":"291","author":"AH Schapira","year":"2004","unstructured":"Schapira, A. H. & Olanow, C. W. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA 291, 358\u2013364 (2004).","journal-title":"JAMA"},{"key":"BFnrd2087_CR97","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1111\/j.1471-4159.1985.tb10556.x","volume":"45","author":"C Mytilineou","year":"1985","unstructured":"Mytilineou, C. & Cohen, G. Deprenyl protects dopamine neurons from the neurotoxic effect of 1-methyl-4-phenylpyridinium ion. J. Neurochem. 45, 1951\u20131953 (1985).","journal-title":"J. Neurochem."},{"key":"BFnrd2087_CR98","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1002\/jnr.490300410","volume":"30","author":"WG Tatton","year":"1991","unstructured":"Tatton, W. G. & Greenwood, C. E. Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J. Neurosci. Res. 30, 666\u2013672 (1991).","journal-title":"J. Neurosci. Res."},{"key":"BFnrd2087_CR99","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/syn.890110410","volume":"11","author":"CC Chiueh","year":"1992","unstructured":"Chiueh, C. C., Huang, S. J. & Murphy, D. L. Enhanced hydroxyl radical generation by 2\u2032-methyl analog of MPTP: suppression by clorgyline and deprenyl. Synapse 11, 346\u2013348 (1992).","journal-title":"Synapse"},{"key":"BFnrd2087_CR100","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/0014-2999(93)90181-G","volume":"243","author":"RM Wu","year":"1993","unstructured":"Wu RM, Chiueh CC, Pert A, Murphy DL. Apparent antioxidant effect of L-deprenyl on hydroxyl radical formation and nigral injury elicited by MPP+ in vivo. Eur. J. Pharmacol. 243, 241\u2013247 (1993).","journal-title":"Eur. J. Pharmacol."},{"key":"BFnrd2087_CR101","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/j.1749-6632.2000.tb06191.x","volume":"899","author":"RM Wu","year":"2000","unstructured":"Wu, R. M., Chen, R. C. & Chiueh, C. C. Effect of MAO-B inhibitors on MPP+ toxicity in vivo. Ann. NY Acad. Sci. 899, 255\u2013261 (2000).","journal-title":"Ann. NY Acad. Sci."},{"key":"BFnrd2087_CR102","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1046\/j.1471-4159.1994.63041572.x","volume":"63","author":"WG Tatton","year":"1994","unstructured":"Tatton, W. G., Ju, W. Y., Holland, D. P., Tai, C. & Kwan, M. (\u2013)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J. Neurochem. 63, 1572\u20131575 (1994).","journal-title":"J. Neurochem."},{"key":"BFnrd2087_CR103","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1523\/JNEUROSCI.18-03-00932.1998","volume":"18","author":"JS Wadia","year":"1998","unstructured":"Wadia, J. S. et al. Mitochondrial membrane potential and nuclear changes in apoptosis caused by serum and nerve growth factor withdrawal: time course and modification by (\u2013)-deprenyl. J. Neurosci. 18, 932\u2013947 (1998).","journal-title":"J. Neurosci."},{"key":"BFnrd2087_CR104","doi-asserted-by":"crossref","unstructured":"Parkinson Disease Study Group Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 328, 176\u2013183 (1993).","DOI":"10.1056\/NEJM199301213280305"},{"key":"BFnrd2087_CR105","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0304-3940(02)00332-4","volume":"326","author":"Y Akao","year":"2002","unstructured":"Akao, Y. et al. An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci. Lett. 326, 105\u2013108 (2002).","journal-title":"Neurosci. Lett."},{"key":"BFnrd2087_CR106","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.neulet.2003.10.067","volume":"355","author":"OB Am","year":"2004","unstructured":"Am, O. B., Amit, T. & Youdim, M. B. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci. Lett. 355, 169\u2013172 (2004).","journal-title":"Neurosci. Lett."},{"key":"BFnrd2087_CR107","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s007020200038","volume":"109","author":"W Maruyama","year":"2002","unstructured":"Maruyama, W., Takahashi, T., Youdim, M. & Naoi, M. The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. J. Neural Transm. 109, 467\u2013481 (2002).","journal-title":"J. Neural Transm."},{"issue":"Suppl. 2","key":"BFnrd2087_CR108","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1212\/WNL.63.7_suppl_2.S13","volume":"63","author":"P Jenner","year":"2004","unstructured":"Jenner, P. Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease. Neurology 63 (Suppl. 2), S13\u2013S22 (2004).","journal-title":"Neurology"},{"key":"BFnrd2087_CR109","doi-asserted-by":"crossref","unstructured":"Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch. Neurol. 61, 561\u2013566 (2004).","DOI":"10.1001\/archneur.61.4.561"},{"key":"BFnrd2087_CR110","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1093\/brain\/awf234","volume":"125","author":"R Grondin","year":"2002","unstructured":"Grondin, R. et al. Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. Brain 125, 2191\u20132201 (2002).","journal-title":"Brain"},{"key":"BFnrd2087_CR111","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1126\/science.290.5492.767","volume":"290","author":"JH Kordower","year":"2000","unstructured":"Kordower, J. H. et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290, 767\u2013773 (2000).","journal-title":"Science"},{"key":"BFnrd2087_CR112","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/1531-8249(199909)46:3<419::AID-ANA21>3.0.CO;2-Q","volume":"46","author":"JH Kordower","year":"1999","unstructured":"Kordower, J. H. et al. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann. Neurol. 46, 419\u2013424 (1999).","journal-title":"Ann. Neurol."},{"key":"BFnrd2087_CR113","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1212\/WNL.60.1.69","volume":"60","author":"JG Nutt","year":"2003","unstructured":"Nutt, J. G. et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60, 69\u201373 (2003).","journal-title":"Neurology"},{"key":"BFnrd2087_CR114","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/nm850","volume":"9","author":"SS Gill","year":"2003","unstructured":"Gill, S. S. et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nature Med. 9, 589\u2013595 (2003).","journal-title":"Nature Med."},{"key":"BFnrd2087_CR115","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/ana.20737","volume":"59","author":"AE Lang","year":"2006","unstructured":"Lang, A. E. et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol. 59, 459\u2013466 (2006).","journal-title":"Ann. Neurol."},{"key":"BFnrd2087_CR116","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S1474-4422(06)70386-6","volume":"5","author":"RA Barker","year":"2006","unstructured":"Barker, R. A. Continuing trials of GDNF in Parkinson's disease. Lancet Neurol. 5, 285\u2013286 (2006).","journal-title":"Lancet Neurol."},{"key":"BFnrd2087_CR117","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/ana.20789","volume":"59","author":"AH Schapira","year":"2006","unstructured":"Schapira, A. H. & Obeso, J. Timing of treatment initiation in Parkinson's disease: a need for reappraisal? Ann. Neurol. 59, 559\u2013562 (2006).","journal-title":"Ann. Neurol."},{"key":"BFnrd2087_CR118","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S1474-4422(06)70373-8","volume":"5","author":"KR Chaudhuri","year":"2006","unstructured":"Chaudhuri, K. R., Healy, D. G. & Schapira, A. H. Non-motor symptoms of Parkinson's disease: diagnosis and management Lancet Neurol. 5, 235\u2013245 (2006).","journal-title":"Lancet Neurol."},{"key":"BFnrd2087_CR119","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S1474-4422(04)00740-9","volume":"3","author":"AE Lang","year":"2004","unstructured":"Lang, A. E. & Obeso, J. A. Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol. 3, 309\u2013316 (2004).","journal-title":"Lancet Neurol."}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrd2087.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrd2087","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrd2087.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:52:18Z","timestamp":1684468338000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrd2087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":119,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["BFnrd2087"],"URL":"https:\/\/doi.org\/10.1038\/nrd2087","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,10]]}}}